Memorial Sloan Kettering Cancer Center’s Post

Traditionally, ovarian cancer treatments were based on observation, surgery, and chemotherapy. But today, ovarian cancer research offers many more treatment options than 15 years ago. Speaking on the role of integrative therapies in ovarian cancer care, Tara Berman, MD, a medical oncologist specializing in gynecology at Inova Schar Cancer, said that it is critical to treat the whole person, not just their cancer. According to a research paper published by Dr. Berman and her colleagues, three components support an integrative approach in ovarian cancer care: mind and body practices, natural products, and lifestyle modification. "Integrative oncology is about using other modalities in conjunction with standard of care to help improve quality of life and ideally, efficacy outcomes," she said. More: https://lnkd.in/eUqBNwa7 Find the abstract of the research here: https://lnkd.in/exnkRz9s #ovariancancer #cancerresearch

#UterineCancer is the most common type of #cancer of the female reproductive tract. In 2021, an estimated 862,875 people in the United States had uterine cancer and nearly 67,880 new diagnoses are expected in 2024. The lifetime risk of developing uterine cancer is 3.1%. There are many factors that can increase your risk, including older age, #obesity, and factors affecting #estrogen levels, like #hormonereplacement therapy or menstrual history. Surgery is often the first treatment for uterine cancer. Typically, surgery for uterine cancer involves an operation called a total #hysterectomy bilateral salpingo-oophorectomy. The surgery removes the uterus, both fallopian tubes and ovaries. #Chemotherapy uses drugs that disrupt the growth of rapidly dividing cells, such as cancer cells. #Radiationtherapy uses high-energy radiation to kill cancer cells. Like chemotherapy, it can be used at all stages of uterine cancer to help shrink the cancer after surgery to help kill remaining cancer cells when there’s a higher risk of the cancer recurring. #Targetedtherapy involves drugs that target certain markers found inside or on the surface of cancer cells. This type of treatment is typically used when uterine cancer is advanced or has recurred. The 5-year overall survival rate in uterine cancer following treatment is 81%. https://lnkd.in/gbEN2AfF #CancerResearch

Does Tamoxifen make a difference in DCIS? A recent publication in the journal Cancer showed that patients that have DCIS (ductal carcinoma in situ, a precancerous breast tumor) and who were compliant with taking their Tamoxifen daily for 5 years were between 6 and 10 % less likely to develop a new breast tumor.  Excellent adherence or compliance means that the patient regularly took the medication as was prescribed without skipping doses.  Low adherence was defined as the patient taking the medication less than 50% of the time.  Good adherence 51-79% of the time and excellent adherence 80% or more of the time.  The range of risk reduction was also affected by whether the patient had radiation therapy after breast conserving surgery (lumpectomy); i.e. if no radiation therapy was given, then the Tamoxifen had a slightly higher impact on decreasing risk of a new tumor.  Additionally, the study showed that there was no statistically significant difference in results if patients had “good” or “low” adherence to taking the medication.  It is notable that even patients that had excellent adherence, there was no effect on dying from breast cancer.  In other words, Tamoxifen can prevent a second breast cancer from occurring but the risk of dying from breast cancer overall is not changed.  In simplest terms, this can be explained that the risk of dying from breast cancer is more weighted by the cancer type, characteristics and subsequent treatment used to combat the second cancer. Adherence to hormonal therapy after surgery among older women with ductal carcinoma in situ: Implications for breast cancer–related adverse health events Jean M. Mitchell PhD, Thomas DeLeire PhD, Claudine Isaacs MD First published: 26 September 2023 https://lnkd.in/eQ7uzPzR

𝑾𝒉𝒂𝒕 𝒊𝒔 𝑪𝒂𝒏𝒄𝒆𝒓? Cancer is a group of diseases characterized by the uncontrolled growth and spread of abnormal cells. If not controlled, cancer can result in death. There are over 100 different types of cancer, and it can develop in almost any organ or tissue, such as the lung, colon, breast, skin, bones, or nerve tissue 𝑪𝒂𝒏𝒄𝒆𝒓 𝑻𝒓𝒆𝒂𝒕𝒎𝒆𝒏𝒕 𝑻𝒆𝒄𝒉𝒏𝒊𝒒𝒖𝒆𝒔 👉 𝗖𝗵𝗲𝗺𝗼𝘁𝗵𝗲𝗿𝗮𝗽𝘆-: Chemotherapy involves the use of drugs to kill or slow the growth of cancer cells. These drugs can be administered orally or intravenously. It can be used as a primary treatment, to shrink tumors before surgery or radiation, to destroy any remaining cancer cells post-surgery, or to alleviate symptoms in advanced cancer stages. 👉 𝗥𝗮𝗱𝗶𝗼𝘁𝗵𝗲𝗿𝗮𝗽𝘆-: Radiotherapy, or radiation therapy, uses high doses of radiation to kill cancer cells or shrink tumors. The high-energy radiation damages the DNA of cancer cells, impairing their ability to reproduce and causing them to die. 👉 𝗦𝘂𝗿𝗴𝗲𝗿𝘆 -: Surgical treatment involves the physical removal of the cancerous tumor from the body. Surgery aims to excise the tumor and, in some cases, surrounding tissues and lymph nodes to ensure the complete removal of cancer cells. @Wingscancercare ** 𝐖𝐢𝐧𝐠𝐬 𝐂𝐚𝐧𝐜𝐞𝐫 𝐂𝐚𝐫𝐞 𝐅𝐨𝐮𝐧𝐝𝐚𝐭𝐢𝐨𝐧, 𝐁𝐞𝐬𝐭 𝐂𝐚𝐧𝐜𝐞𝐫 𝐍𝐆𝐎 𝐈𝐧 𝐆𝐡𝐚𝐳𝐢𝐚𝐛𝐚𝐝 . 𝐎𝐮𝐫 𝐂𝐨𝐧𝐭𝐚𝐜𝐭 𝐃𝐞𝐭𝐚𝐢𝐥𝐬:- . 📧 𝐰𝐢𝐧𝐠𝐬𝐜𝐚𝐧𝐜𝐞𝐫𝐜𝐚𝐫𝐞@𝐠𝐦𝐚𝐢𝐥.𝐜𝐨𝐦 . 📳 (+𝟗𝟏) 𝟗𝟖𝟓𝟔𝟑𝟓𝟗𝟐𝟗𝟓 . 📍 𝟑𝟖𝟗 𝐍𝐢𝐭𝐢 𝐊𝐡𝐚𝐧𝐝 𝐈𝐧𝐝𝐢𝐫𝐚𝐩𝐮𝐫𝐚𝐦, 𝐆𝐡𝐚𝐳𝐢𝐚𝐛𝐚𝐝 . 👉 𝐡𝐭𝐭𝐩𝐬://𝐰𝐢𝐧𝐠𝐬𝐜𝐚𝐧𝐜𝐞𝐫𝐜𝐚𝐫𝐞.𝐜𝐨𝐦 . #Wingscancercarefoundation #DrRichaAgrawal #neckcancer #drrekhaarya #cáncer #cervicalcancer #pregnancy #pregnancyaftercancer #metastaticbreatcancer #menopausehealth #breastcancer #brestpain #brestpainter #breastpain #breastpains

Cervical cancer is one of the most preventable and treatable gynecologic cancers, thanks to the Pap smear. This screening test involves collecting cells from the cervix to detect abnormal changes. Early identification of precancerous lesions can lead to interventions such as the removal of abnormal cells, preventing the progression of #cervicalcancer. Regular #PapSmears are typically recommended every three years for women aged 21-65, and are crucial for early detection. Early detection of cervical cancer can have a profound impact on treatment outcomes and overall survival rates. Cervical cancer, when detected in their early stages, are often more treatable and associated with higher survival rates. Also, early-stage cervical cancer may require less aggressive treatment, such as surgery or localized radiation therapy, leading to fewer side effects and a better quality of life for patients. https://lnkd.in/eFT6zZfN #cancerresearch

【New surgical treatment reduces the risk of disease recurrence in bladder cancer patients】CU Medicine has conducted the world’s first randomised clinical trial that demonstrates a significant benefit from en bloc resection of bladder tumour (ERBT) in reducing cancer recurrence by 40%, compared with conventional transurethral resection of bladder tumour (TURBT). Bladder cancer is a major urological disease and among the top 10 most common cancers in the world. About 75% of bladder cancer patients present with non-muscle-invasive bladder cancer with a tumour size about 3cm or smaller. TURBT is the conventional standard resection, which involves using a cystoscope to enter the bladder through the urethra, and then resecting the bladder tumour in a piecemeal manner. However, this kind of resection results in floating tumour cells, which can reimplant on the bladder wall and lead to cancer recurrence. ERBT has been proposed as an alternative technique for treating non-muscle-invasive bladder cancer. The chance of cancer recurrence after ERBT could be reduced, as the tumour is removed in one piece and the risk of cancer cell reimplantation is low. Complete tumour resection can be ascertained by cell examination under a microscope. In this multicentre study, 350 bladder cancer patients from 13 hospitals in Hong Kong were randomly assigned to receive ERBT or TURBT at a 1:1 ratio. The tumour size of all participants was 3cm or smaller. Results show that, after adjusting for patient and disease factors, the risk of cancer recurrence in patients receiving ERBT is 40% lower than that in those receiving TURBT. This study is a milestone in proving ERBT can be the first-line surgical treatment for bladder cancer patients with a non-muscle-invasive tumour of 3cm or smaller. Details of the study have been published in the prestigious international journal European Urology. Details: https://bit.ly/3VoctPA Full article of the study: https://bit.ly/4cgnNo2 #CUMedicine #Bladder #Cancer

📃Scientific paper: Comparison of surgical and oncological outcomes between different surgical approaches for overweight or obese cervical cancer patients Abstract: The purpose was to investigate the safety and advantages of different surgical approaches applied to overweight or obese cervical cancer patients by comparing their surgical and oncological outcomes. This is a retrospective cohort study. 382 patients with a body mass index of at least 24.0 kg/m^2 and stage IB-IIA (The International Federation of Gynecology and Obstetrics, FIGO 2009) cervical cancer were enrolled, and then were divided into three groups: open radical hysterectomy (ORH) group, laparoscopic radical hysterectomy (LRH) group, and robot-assisted radical hysterectomy (RRH) group according to the surgical approach. IBM SPSS version 25.0 was used to analyze data. There were 51 patients in ORH group, 225 patients in LRH group and 106 patients in RRH group. In the comparison of surgical outcomes, compared to LRH and ORH, RRH had the shortest operating time, the least estimated blood loss, the shortest postoperative hospital stay, and the shortest recovery time for bowel function ( P  < 0.05). In the comparison of postoperative complications, ORH has the highest rate of postoperative infection and wound complication compared to LRH and RRH ( P  < 0.05), and RRH has the highest proportion of urinary retention. After a median follow-up time of 61 months, there was no statistically significant difference between the three groups in terms of 5-year overall survival (OS) rate and 5-year recurrence-free survival (RFS) rate, ( P  = 0.262, P  = 0.453). In patients with... Continued on ES/IODE ➡️ https://etcse.fr/G7hy ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.

Interesting new research about radical cystectomy (RC) in women…   RC is recommended for patients with non-muscle-invasive bladder cancer for whom BCG immunotherapy has failed – that’s around 50% of high-risk cases. However, many patients are unwilling to undergo RC because of its impact on quality of life. While bladder cancer is more common in men than women, women typically present later and therefore with more aggressive cancer, meaning that they are more likely to receive more radical treatment than men.     For women, classic RC involves en bloc removal not just of the bladder but also the ovaries, uterus and the upper part of the vagina. However, previous studies have found uterus invasion to be comparatively rare, in the range 0.3-12.5% (1).   In a new retrospective multicentre study (2) – believed to be the largest of its type – malignant gynaecological organ involvement (GOI) was seen in 6.6% of patients, 3% had involvement of more than one gynaecological organ, and none had a primary gynaecological malignancy detected incidentally at RC. Patients with GOI were more likely to have cT3/T4 stage than those without GOI. Furthermore, cT4 stage was found to be an independent predictor of malignant GOI (p>0.001).   The authors suggest that “in the absence of clinical or radiological evidence of sexual organ involvement, our results do not support their routine removal at the time of RC”.   Combat’s HIVEC® (intravesical hyperthermic chemotherapy) treatment offers a bladder-sparing alternative to patients with high-risk, non-muscle-invasive bladder cancer who don’t want to undergo RC if BCG therapy fails. A recent study found Combat’s HIVEC® was a “well-tolerated and safe bladder-sparing treatment… an alternative treatment option for patients who refuse or are unfit for RC” (3).   1. Huang et al. Is hysterectomy beneficial in radical cystectomy for female patients with urothelial carcinoma of bladder? A retrospective analysis of consecutive 112 cases from a single institution (2019), BMC Urology    2. Lobo et al. Gynaecological organ involvement in females undergoing radical cystectomy: a multicentre study (2024), BJUI 3. Pijpers et al. Long-term efficacy of hyperthermic intravesical chemotherapy for BCG-unresponsive non-muscle invasive bladder cancer (2021), Urologic Oncology #medicalinnovation #HVEC #bladdercancer #hysterectomy #CombatMedical

Interesting new research about radical cystectomy (RC) in women…   RC is recommended for patients with non-muscle-invasive bladder cancer for whom BCG immunotherapy has failed – that’s around 50% of high-risk cases. However, many patients are unwilling to undergo RC because of its impact on quality of life. While bladder cancer is more common in men than women, women typically present later and therefore with more aggressive cancer, meaning that they are more likely to receive more radical treatment than men.    For women, classic RC involves en bloc removal not just of the bladder but also the ovaries, uterus and the upper part of the vagina. However, previous studies have found uterus invasion to be comparatively rare, in the range 0.3-12.5% (1).   In a new retrospective multicentre study (2) – believed to be the largest of its type – malignant gynaecological organ involvement (GOI) was seen in 6.6% of patients, 3% had involvement of more than one gynaecological organ, and none had a primary gynaecological malignancy detected incidentally at RC. Patients with GOI were more likely to have cT3/T4 stage than those without GOI. Furthermore, cT4 stage was found to be an independent predictor of malignant GOI (p>0.001).   The authors suggest that “in the absence of clinical or radiological evidence of sexual organ involvement, our results do not support their routine removal at the time of RC”.   Combat’s HIVEC® (intravesical hyperthermic chemotherapy) treatment offers a bladder-sparing alternative to patients with high-risk, non-muscle-invasive bladder cancer who don’t want to undergo RC if BCG therapy fails. A recent study found Combat’s HIVEC® was a “well-tolerated and safe bladder-sparing treatment… an alternative treatment option for patients who refuse or are unfit for RC” (3).   1. Huang et al. Is hysterectomy beneficial in radical cystectomy for female patients with urothelial carcinoma of bladder? A retrospective analysis of consecutive 112 cases from a single institution (2019), BMC Urology   2. Lobo et al. Gynaecological organ involvement in females undergoing radical cystectomy: a multicentre study (2024), BJUI 3. Pijpers et al. Long-term efficacy of hyperthermic intravesical chemotherapy for BCG-unresponsive non-muscle invasive bladder cancer (2021), Urologic Oncology #medicalinnovation #HVEC #bladdercancer #hysterectomy #CombatMedical

Development of new treatment options for osteosarcoma (OS) patients has gained more support thanks to a $4.49 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT), announced this week. Richard Gorlick, M.D., division head of Pediatrics at The University of Texas MD Anderson Cancer Center, serves as the Principal Investigator of the grant, titled “Novel Therapies in Osteosarcoma.” The multi-investigator research award (MIRA) seeks to find protein targets for osteosarcoma and exploit them with immune- and cytotoxic-based approaches. Other study investigators include Shulin Li, PhD, Elizabeth Shpall, M.D., Tim Heffernan, Ph.D., Bissan Al-Lazikani, Ph.D., Jing Wang, Ph.D., Yisheng Li,Ph.D., and Samir Hanash, M.D., Ph.D.   Proud to be part of this team as therapies for pediatric, teen and young adult osteosarcoma patients have not changed in decades.   The grant also supports researchers in further developing minimally invasive tests that may determine which patients will or will not respond to therapy; developing new therapies which overcome drug resistance; and developing blood tests which can provide information that will define our next generation of treatments. Since its inception, CPRIT has awarded nearly $3.6 billion in grants for cancer research. Learn more about this osteosarcoma grant and CPRIT: https://bit.ly/4fU0G5a #CancerResearch #EndCancer #pediatricsarcoma #osteosarcoma #sarcomaresearch #OneMDAnderson #CureSarcoma #pediatriccancer #pediatriconcology #CPRIT